WHAT IS CLAIMED:

1. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides complementary within nucleobases 30-49, 48-63, 150-169, 151-170, 152-171, 154-169, 154-173, 156-171, 156-175, 157-176, 158-173, 158-177, 480-499, 600-619, 638-657, 644-663, 738-757, 1089-1108, 1135-1154, 1141-1160, 1147-1166, 1150-1169, 1153-1172, 1159-1178, 1162-1181, 1165-1184, 1171-1186, 1171-1190, 1173-1188, 1173-1192, 1175-1190, 1175-1194, 1177-1196, 1183-1202, 1208-1227, 1235-1254, 1298-1317, 1304-1323, 1310-1329, 1316-1335, 1319-1338, 1322-1341, 1328-1347, 1349-1368, 1355-1374, 1393-1412, 1396-1415, 1399-1418, 1405-1424, 1421-1440, 1621-1640, 1646-1665, 1646-1665, 1647-1666, 1689-1708, 1749-1768, 1763-1782, 1912-1931, 2073-2092, 2085-2104, 2166-2185, 2172-2191, 2189-2208, 2191-2210, 2193-2212, 2195-2210, 2195-2214, 2196-2215, 2197-2212, 2197-2216, 2202-2221, 2223-2238, 2223-2242, 2225-2240, 2226-2245, 2227-2242, 2227-2246, 2238-2257, 2241-2260, 2267-2286, 2361-2380, 2388-2407, 2397-2416, 2448-2467, 2453-2472, 2455-2474, 2457-2472, 2457-2476, 2459-2474, 2459-2478, 2461-2476, 2461-2480, 2532-2551, 2550-2569, 2551-2566, 2551-2570, 2552-2568, 2552-2570, 2552-2571, 2553-2568, 2553-2570, 2553-2571, 2553-2572, 2554-2571, 2554-2572, 2554-2573, 2555-2570, 2555-2572, 2555-2574, 2556-2573, 2556-2574, 2556-2575, 2557-2573, 2557-2574, 2557-2575, 2557-2576, 2558-2575, 2558-2576, 2558-2577, 2559-2576, 2559-2577, 2559-2578, 2560-2577, 2560-2578, 2560-2579, 2561-2576, 2561-2578, 2561-2579, 2561-2580, 2562-2577, 2562-2579, 2562-2581, 2563-2578, 2563-2580, 2563-2582, 2564-2581, 2564-2583, 2565-2584, 2566-2583, 2566-2585, 2567-2582, 2567-2584, 2567-2586, 2568-2583, 2568-2585, 2568-2587, 2569-2586, 2569-2588, 2570-2585, 2570-2587, 2570-2589, 2571-2586, 2571-2588, 2571-2590, 2572-2589, 2572-2590, 2572-2591, 2573-2590, 2573-2592, 2574-2590, 2574-2591, 2574-2593, 2575-2590, 2575-2591, 2575-2592, 2575-2594, 2576-2593, 2576-2595, 2577-2594, 2577-2595, 2577-2596, 2578-2594, 2578-2596, 2578-2597, 2579-2598, 2580-2596, 2580-2597, 2580-2598, 2580-2599, 2581-2597, 2581-2598, 2581-2599, 2581-2600, 2582-2598, 2582-2599, 2582-2600, 2582-2601, 2583-2599, 2583-2600, 2583-2601, 2583-2602, 2584-2600, 2584-2601, 2584-2602, 2584-2603, 2585-2601, 2585-2603, 2585-2604, 2586-2601, 2586-2602, 2586-2604, 2586-2605, 2587-2602, 2587-2603, 2587-2605, 2587-2606, 2588-2603, 2588-2604, 2588-2605, 2588-2606, 2588-2607, 2589-2604, 2589-2605, 2589-2606, 2589-2607, 2589-2608, 2590-2605, 2590-2606, 2590-2607, 2590-2608, 2590-2609, 2590-2609, 2591-2607, 2591-2608, 2591-2609, 2591-2610, 2592-2607, 2592-2608, 2592-2609, 2592-2610, 2592-2611, 2593-2608, 2593-2609, 2593-2610, 2593-2612, 2594-2609, 2594-2610, 2594-2611, 2594-2612, 2594-2613, 2595-2610, 2595-2611, 2595-2612, 2595-2613, 2595-2614, 2596-2611, 2596-2612, 2596-2613, 2596-2614, 2596-2615, 2597-2612, 2597-2612, 2597-2613, 2597-2614, 2597-2615, 2597-2616, 2598-2613, 2598-2614, 2598-2615, 2598-2616, 2598-2617, 2599-2614, 2599-2615, 2599-2616, 2599-2617, 2599-2618, 2600-2615, 2600-2616, 2600-2617, 2600-2618, 2600-2619, 2601-2616, 2601-2617, 2601-2618, 2601-2619, 2601-2620, 2602-2617, 2602-2618, 2602-2619, 2602-2620, 2602-2621, 2603-2618, 2603-2619, 2603-

2620, 2603-2621, 2603-2622, 2604-2619, 2604-2620, 2604-2621, 2604-2622, 2604-2623, 2605-2620, 2605-2621, 2605-2622, 2605-2623, 2605-2624, 2606-2621, 2606-2622, 2606-2623, 2606-2624, 2606-2625, 2607-2622, 2607-2623, 2607-2624, 2607-2625, 2607-2626, 2608-2623, 2608-2624, 2608-2625, 2608-2626, 2608-2627, 2609-2624, 2609-2625, 2609-2626, 2609-2627, 2609-2628, 2610-2625, 2610-2626, 2610-2627, 2610-2628, 2610-2629, 2611-2626, 2611-2627, 2611-2628, 2611-2629, 2611-2630, 2612-2627, 2612-2628, 2612-2629, 2612-2630, 2612-2631, 2613-2628, 2613-2629, 2613-2630, 2613-2631, 2614-2629, 2614-2630, 2614-2631, 2615-2630, 2615-2631, or 2616-2631 of SEQ ID NO: 1, and wherein said modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1.

2. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 30-49, 48-63, 150-169, 151-170, 152-171, 154-169, 154-173, 156-171, 156-175, 157-176, 158-173, 158-177, 480-499, 600-619, 638-657, 644-663, 738-757, 1089-1108, 1135-1154, 1141-1160, 1147-1166, 1150-1169, 1153-1172, 1159-1178, 1162-1181, 1165-1184, 1171-1186, 1171-1190, 1173-1188, 1173-1192, 1175-1190, 1175-1194, 1177-1196, 1183-1202, 1208-1227, 1235-1254, 1298-1317, 1304-1323, 1310-1329, 1316-1335, 1319-1338, 1322-1341, 1328-1347, 1349-1368, 1355-1374, 1393-1412, 1396-1415, 1399-1418, 1405-1424, 1421-1440, 1621-1640, 1646-1665, 1646-1665, 1647-1666, 1689-1708, 1749-1768, 1763-1782, 1912-1931, 2073-2092, 2085-2104, 2166-2185, 2172-2191, 2189-2208, 2191-2210, 2193-2212, 2195-2210, 2195-2214, 2196-2215, 2197-2212, 2197-2216, 2202-2221, 2223-2238, 2223-2242, 2225-2240, 2226-2245, 2227-2242, 2227-2246, 2238-2257, 2241-2260, 2267-2286, 2361-2380, 2388-2407, 2397-2416, 2448-2467, 2453-2472, 2455-2474, 2457-2472, 2457-2476, 2459-2474, 2459-2478, 2461-2476, 2461-2480, 2532-2551, 2550-2569, 2551-2566, 2551-2570, 2552-2568, 2552-2570, 2552-2571, 2553-2568, 2553-2570, 2553-2571, 2553-2572, 2554-2571, 2554-2572, 2554-2573, 2555-2570, 2555-2572, 2555-2574, 2556-2573, 2556-2574, 2556-2575, 2557-2573, 2557-2574, 2557-2575, 2557-2576, 2558-2575, 2558-2576, 2558-2577, 2559-2576, 2559-2577, 2559-2578, 2560-2577, 2560-2578, 2560-2579, 2561-2576, 2561-2578, 2561-2579, 2561-2580, 2562-2577, 2562-2579, 2562-2581, 2563-2578, 2563-2580, 2563-2582, 2564-2581, 2564-2583, 2565-2584, 2566-2583, 2566-2585, 2567-2582, 2567-2584, 2567-2586, 2568-2583, 2568-2585, 2568-2587, 2569-2586, 2569-2588, 2570-2585, 2570-2587, 2570-2589, 2571-2586, 2571-2588, 2571-2590, 2572-2589, 2572-2590, 2572-2591, 2573-2590, 2573-2592, 2574-2590, 2574-2591, 2574-2593, 2575-2590, 2575-2591, 2575-2592, 2575-2594, 2576-2593, 2576-2595, 2577-2594, 2577-2595, 2577-2596, 2578-2594, 2578-2596, 2578-2597, 2579-2598, 2580-2596, 2580-2597, 2580-2598, 2580-2599, 2581-2597, 2581-2598, 2581-2599, 2581-2600, 2582-2598, 2582-2599, 2582-2600, 2582-2601, 2583-2599, 2583-2600, 2583-2601, 2583-2602, 2584-2600, 2584-2601, 2584-2602, 2584-2603, 2585-2601, 2585-2603, 2585-2604, 2586-2601, 2586-2602, 2586-2604, 2586-2605, 2587-2602, 2587-2603, 2587-2605, 2587-2606, 2588-2603, 2588-2604, 2588-2605, 2588-2606, 2588-2607, 2589-2604, 2589-2605, 2589-2606, 2589-2607, 2589-2608, 2590-2605,

2590-2606, 2590-2607, 2590-2608, 2590-2609, 2590-2609, 2591-2607, 2591-2608, 2591-2609, 2591-2610, 2592-2607, 2592-2608, 2592-2609, 2592-2610, 2592-2611, 2593-2608, 2593-2609, 2593-2610, 2593-2612, 2594-2609, 2594-2610, 2594-2611, 2594-2612, 2594-2613, 2595-2610, 2595-2611, 2595-2612, 2595-2613, 2595-2614, 2596-2611, 2596-2612, 2596-2613, 2596-2614, 2596-2615, 2597-2612, 2597-2612, 2597-2613, 2597-2614, 2597-2615, 2597-2616, 2598-2613, 2598-2614, 2598-2615, 2598-2616, 2598-2617, 2599-2614, 2599-2615, 2599-2616, 2599-2617, 2599-2618, 2600-2615, 2600-2616, 2600-2617, 2600-2618, 2600-2619, 2601-2616, 2601-2617, 2601-2618, 2601-2619, 2601-2620, 2602-2617, 2602-2618, 2602-2619, 2602-2620, 2602-2621, 2603-2618, 2603-2619, 2603-2620, 2603-2621, 2603-2622, 2604-2619, 2604-2620, 2604-2621, 2604-2622, 2604-2623, 2605-2620, 2605-2621, 2605-2622, 2605-2623, 2605-2624, 2606-2621, 2606-2622, 2606-2623, 2606-2624, 2606-2625, 2607-2622, 2607-2623, 2607-2624, 2607-2625, 2607-2626, 2608-2623, 2608-2624, 2608-2625, 2608-2626, 2608-2627, 2609-2624, 2609-2625, 2609-2626, 2609-2627, 2609-2628, 2610-2625, 2610-2626, 2610-2627, 2610-2628, 2610-2629, 2611-2626, 2611-2627, 2611-2628, 2611-2629, 2611-2630, 2612-2627, 2612-2628, 2612-2629, 2612-2630, 2612-2631, 2613-2628, 2613-2629, 2613-2630, 2613-2631, 2614-2629, 2614-2630, 2614-2631, 2615-2630, 2615-2631, or 2616-2631 of SEQ ID NO:1, and wherein the nucleobase sequence of the modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1.

3. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides complementary within nucleobases 1608-1627, 1685-1704, 1686-1705, 1751-1770, 1769-1784, 1871-1890, 1872-1891, 1873-1892, 1875-1890, 1875-1894, 1877-1892, 1877-1896, 1878-1897, 1879-1894, 1879-1898, 2288-2307, 2808-2827, 2846-2865, 2852-2871, 2946-2965, 3773-3792, 3819-3838, 3825-3844, 3831-3850, 3834-3853, 3837-3856, 3843-3862, 4151-4166, 4151-4170, 4153-4172, 4159-4178, 4184-4203, 4211-4230, 4609-4628, 4612-4631, 4615-4634, 4621-4640, 4642-4661, 4648-4667, 4686-4705, 4689-4708, 4692-4711, 4698-4717, 4714-4733, 5270-5289, 5295-5314, 5296-5315, 5830-5849, 5890-5909, 5904-5923, 6406-6425, 6662-6681, 6674-6693, 6954-6973, 6960-6979, 6977-6996, 6979-6998, 6981-7000, 6983-6998, 6983-7002, 6984-7003, 6985-7000, 6985-7004, 6990-7009, 7122-7141, 7125-7144, 7151-7170, 7353-7372, 7362-7381, 7683-7702, 7688-7707, 7690-7709, 7692-7707, 7692-7711, 7694-7709, 7694-7713, 7696-7711, 7696-7715, 7767-7786, 7785-7804, 7786-7801, 7787-7803, 7787-7805, 7787-7806, 7788-7803, 7788-7805, 7788-7806, 7788-7807, 7789-7806, 7789-7807, 7789-7808, 7790-7805, 7790-7807, 7790-7809, 7791-7808, 7791-7809, 7791-7810, 7792-7808, 7792-7809, 7792-7810, 7792-7811, 7793-7810, 7793-7811, 7793-7812, 7794-7811, 7794-7812, 7794-7813, 7795-7812, 7795-7813, 7795-7814, 7796-7811, 7796-7813, 7796-7814, 7796-7815, 7797-7812, 7797-7814, 7797-7816, 7798-7813, 7798-7815, 7798-7817, 7799-7816, 7799-7818, 7800-7819, 7801-7818, 7801-7820, 7802-7817, 7802-7819, 7802-7821, 7803-7818, 7803-7820, 7803-7822, 7804-7821, 7804-7823, 7805-7820, 7805-7822, 7805-7824, 7806-7821, 7806-7823, 7806-7825, 7807-7824, 7807-7825, 7807-7826, 7808-7825, 7808-7827, 7809-7825, 7809-7826, 7809-7828, 7810-7825, 7810-7826, 7810-7827, 7810-7829, 7811-7828, 7811-7830, 7812-

7829, 7812-7830, 7812-7831, 7813-7829, 7813-7831, 7813-7832, 7814-7833, 7815-7831, 7815-7832, 7815-7833, 7815-7834, 7816-7832, 7816-7833, 7816-7834, 7816-7835, 7817-7833, 7817-7834, 7817-7835, 7817-7836, 7818-7834, 7818-7835, 7818-7836, 7818-7837, 7819-7835, 7819-7836, 7819-7837, 7819-7838, 7820-7836, 7820-7838, 7820-7839, 7821-7836, 7821-7837, 7821-7839, 7821-7840, 7822-7837, 7822-7838, 7822-7840, 7822-7841, 7823-7838, 7823-7839, 7823-7839, 7823-7840, 7823-7841, 7823-7842, 7824-7839, 7824-7840, 7824-7840, 7824-7841, 7824-7842, 7824-7843, 7825-7840, 7825-7841, 7825-7842, 7825-7843, 7825-7844, 7826-7842, 7826-7843, 7826-7844, 7826-7845, 7827-7842, 7827-7843, 7827-7844, 7827-7845, 7827-7846, 7828-7843, 7828-7844, 7828-7845, 7828-7847, 7829-7844, 7829-7845, 7829-7846, 7829-7847, 7829-7848, 7830-7845, 7830-7846, 7830-7847, 7830-7848, 7830-7849, 7831-7846, 7831-7847, 7831-7848, 7831-7849, 7831-7850, 7832-7847, 7832-7848, 7832-7849, 7832-7850, 7832-7851, 7833-7848, 7833-7849, 7833-7850, 7833-7851, 7833-7852, 7834-7849, 7834-7850, 7834-7851, 7834-7852, 7834-7853, 7835-7850, 7835-7851, 7835-7852, 7835-7853, 7835-7854, 7836-7851, 7836-7852, 7836-7853, 7836-7854, 7836-7855, 7837-7852, 7837-7853, 7837-7854, 7837-7855, 7837-7856, 7838-7853, 7838-7854, 7838-7855, 7838-7856, 7838-7857, 7839-7854, 7839-7855, 7839-7856, 7839-7857, 7839-7858, 7840-7855, 7840-7856, 7840-7857, 7840-7858, 7840-7859, 7841-7856, 7841-7857, 7841-7858, 7841-7859, 7841-7860, 7842-7857, 7842-7858, 7842-7859, 7842-7860, 7842-7861, 7843-7858, 7843-7859, 7843-7860, 7843-7861, 7843-7862, 7844-7859, 7844-7860, 7844-7861, 7844-7862, 7845-7860, 7845-7861, 7845-7862, 7846-7861, or 7846-7862 of SEQ ID NO: 2, and wherein said modified oligonucleotide at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 2.

4. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 1608-1627, 1685-1704, 1686-1705, 1751-1770, 1769-1784, 1871-1890, 1872-1891, 1873-1892, 1875-1890, 1875-1894, 1877-1892, 1877-1896, 1878-1897, 1879-1894, 1879-1898, 2288-2307, 2808-2827, 2846-2865, 2852-2871, 2946-2965, 3773-3792, 3819-3838, 3825-3844, 3831-3850, 3834-3853, 3837-3856, 3843-3862, 4151-4166, 4151-4170, 4153-4172, 4159-4178, 4184-4203, 4211-4230, 4609-4628, 4612-4631, 4615-4634, 4621-4640, 4642-4661, 4648-4667, 4686-4705, 4689-4708, 4692-4711, 4698-4717, 4714-4733, 5270-5289, 5295-5314, 5296-5315, 5830-5849, 5890-5909, 5904-5923, 6406-6425, 6662-6681, 6674-6693, 6954-6973, 6960-6979, 6977-6996, 6979-6998, 6981-7000, 6983-6998, 6983-7002, 6984-7003, 6985-7000, 6985-7004, 6990-7009, 7122-7141, 7125-7144, 7151-7170, 7353-7372, 7362-7381, 7683-7702, 7688-7707, 7690-7709, 7692-7707, 7692-7711, 7694-7709, 7694-7713, 7696-7711, 7696-7715, 7767-7786, 7785-7804, 7786-7801, 7787-7803, 7787-7805, 7787-7806, 7788-7803, 7788-7805, 7788-7806, 7788-7807, 7789-7806, 7789-7807, 7789-7808, 7790-7805, 7790-7807, 7790-7809, 7791-7808, 7791-7809, 7791-7810, 7792-7808, 7792-7809, 7792-7810, 7792-7811, 7793-7810, 7793-7811, 7793-7812, 7794-7811, 7794-7812, 7794-7813, 7795-7812, 7795-7813, 7795-7814, 7796-7811, 7796-7813, 7796-7814, 7796-7815, 7797-7812, 7797-7814, 7797-7816,

7798-7813, 7798-7815, 7798-7817, 7799-7816, 7799-7818, 7800-7819, 7801-7818, 7801-7820, 7802-7817, 7802-7819, 7802-7821, 7803-7818, 7803-7820, 7803-7822, 7804-7821, 7804-7823, 7805-7820, 7805-7822, 7805-7824, 7806-7821, 7806-7823, 7806-7825, 7807-7824, 7807-7825, 7807-7826, 7808-7825, 7808-7827, 7809-7825, 7809-7826, 7809-7828, 7810-7825, 7810-7826, 7810-7827, 7810-7829, 7811-7828, 7811-7830, 7812-7829, 7812-7830, 7812-7831, 7813-7829, 7813-7831, 7813-7832, 7814-7833, 7815-7831, 7815-7832, 7815-7833, 7815-7834, 7816-7832, 7816-7833, 7816-7834, 7816-7835, 7817-7833, 7817-7834, 7817-7835, 7817-7836, 7818-7834, 7818-7835, 7818-7836, 7818-7837, 7819-7835, 7819-7836, 7819-7837, 7819-7838, 7820-7836, 7820-7838, 7820-7839, 7821-7836, 7821-7837, 7821-7839, 7821-7840, 7822-7837, 7822-7838, 7822-7840, 7822-7841, 7823-7838, 7823-7839, 7823-7839, 7823-7840, 7823-7841, 7823-7842, 7824-7839, 7824-7840, 7824-7840, 7824-7841, 7824-7842, 7824-7843, 7825-7840, 7825-7841, 7825-7842, 7825-7843, 7825-7844, 7826-7842, 7826-7843, 7826-7844, 7826-7845, 7827-7842, 7827-7843, 7827-7844, 7827-7845, 7827-7846, 7828-7843, 7828-7844, 7828-7845, 7828-7847, 7829-7844, 7829-7845, 7829-7846, 7829-7847, 7829-7848, 7830-7845, 7830-7846, 7830-7847, 7830-7848, 7830-7849, 7831-7846, 7831-7847, 7831-7848, 7831-7849, 7831-7850, 7832-7847, 7832-7848, 7832-7849, 7832-7850, 7832-7851, 7833-7848, 7833-7849, 7833-7850, 7833-7851, 7833-7852, 7834-7849, 7834-7850, 7834-7851, 7834-7852, 7834-7853, 7835-7850, 7835-7851, 7835-7852, 7835-7853, 7835-7854, 7836-7851, 7836-7852, 7836-7853, 7836-7854, 7836-7855, 7837-7852, 7837-7853, 7837-7854, 7837-7855, 7837-7856, 7838-7853, 7838-7854, 7838-7855, 7838-7856, 7838-7857, 7839-7854, 7839-7855, 7839-7856, 7839-7857, 7839-7858, 7840-7855, 7840-7856, 7840-7857, 7840-7858, 7840-7859, 7841-7856, 7841-7857, 7841-7858, 7841-7859, 7841-7860, 7842-7857, 7842-7858, 7842-7859, 7842-7860, 7842-7861, 7843-7858, 7843-7859, 7843-7860, 7843-7861, 7843-7862, 7844-7859, 7844-7860, 7844-7861, 7844-7862, 7845-7860, 7845-7861, 7845-7862, 7846-7861, and 7846-7862 of SEQ ID NO: 2, and wherein the nucleobase sequence of the modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 2.

5. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide is targeted to the 3'UTR of a CFB nucleic acid.

6. The compound of claim 5, wherein the modified oligonucleotide targets within nucleotides 2574-2626 of a CFB nucleic acid having the nucleobase sequence of SEQ ID NO: 1.

7. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 2457-2631, 2457-2472, 2457-2474, 2457-2476, 2457-2566, 2457-2570, 2457-2571, 2457-2572, 2457-2573, 2457-2574, 2457-2575, 2457-2576, 2457-2577, 2457-2578, 2457-2579, 2457-2580, 2457-2581, 2457-2582, 2457-2583, 2457-2584, 2457-2585, 2457-2586, 2457-2587, 2457-2588, 2457-2589, 2457-2590, 2457-2591, 2457-2592, 2457-2593, 2457-2594, 2457-2595, 2457-2596, 2457-2597, 2457-2598, 2457-2599, 2457-2600, 2457-2601, 2457-2602, 2457-2603, 2457-2604, 2457-2605, 2457-2606, 2457-2607, 2457-2608, 2457-2609, 2457-

2610, 2457-2611, 2457-2612, 2457-2613, 2457-2614, 2457-2615, 2457-2616, 2457-2617, 2457-2618, 2457-2619, 2457-2620, 2457-2621, 2457-2622, 2457-2623, 2457-2624, 2457-2625, 2457-2626, 2457-2627, 2457-2628, 2457-2629, 2457-2630, 2457-2631, 2459-2474, 2459-2476, 2459-2566, 2459-2570, 2459-2571, 2459-2572, 2459-2573, 2459-2574, 2459-2575, 2459-2576, 2459-2577, 2459-2578, 2459-2579, 2459-2580, 2459-2581, 2459-2582, 2459-2583, 2459-2584, 2459-2585, 2459-2586, 2459-2587, 2459-2588, 2459-2589, 2459-2590, 2459-2591, 2459-2592, 2459-2593, 2459-2594, 2459-2595, 2459-2596, 2459-2597, 2459-2598, 2459-2599, 2459-2600, 2459-2601, 2459-2602, 2459-2603, 2459-2604, 2459-2605, 2459-2606, 2459-2607, 2459-2608, 2459-2609, 2459-2610, 2459-2611, 2459-2612, 2459-2613, 2459-2614, 2459-2615, 2459-2616, 2459-2617, 2459-2618, 2459-2619, 2459-2620, 2459-2621, 2459-2622, 2459-2623, 2459-2624, 2459-2625, 2459-2626, 2459-2627, 2459-2628, 2459-2629, 2459-2630, 2459-2631, 2461-2476, 2461-2566, 2461-2570, 2461-2571, 2461-2572, 2461-2573, 2461-2574, 2461-2575, 2461-2576, 2461-2577, 2461-2578, 2461-2579, 2461-2580, 2461-2581, 2461-2582, 2461-2583, 2461-2584, 2461-2585, 2461-2586, 2461-2587, 2461-2588, 2461-2589, 2461-2590, 2461-2591, 2461-2592, 2461-2593, 2461-2594, 2461-2595, 2461-2596, 2461-2597, 2461-2598, 2461-2599, 2461-2600, 2461-2601, 2461-2602, 2461-2603, 2461-2604, 2461-2605, 2461-2606, 2461-2607, 2461-2608, 2461-2609, 2461-2610, 2461-2611, 2461-2612, 2461-2613, 2461-2614, 2461-2615, 2461-2616, 2461-2617, 2461-2618, 2461-2619, 2461-2620, 2461-2621, 2461-2622, 2461-2623, 2461-2624, 2461-2625, 2461-2626, 2461-2627, 2461-2628, 2461-2629, 2461-2630, 2461-2631, 2551-2566, 2551-2570, 2551-2571, 2551-2572, 2551-2573, 2551-2574, 2551-2575, 2551-2576, 2551-2577, 2551-2578, 2551-2579, 2551-2580, 2551-2581, 2551-2582, 2551-2583, 2551-2584, 2551-2585, 2551-2586, 2551-2587, 2551-2588, 2551-2589, 2551-2590, 2551-2591, 2551-2592, 2551-2593, 2551-2594, 2551-2595, 2551-2596, 2551-2597, 2551-2598, 2551-2599, 2551-2600, 2551-2601, 2551-2602, 2551-2603, 2551-2604, 2551-2605, 2551-2606, 2551-2607, 2551-2608, 2551-2609, 2551-2610, 2551-2611, 2551-2612, 2551-2613, 2551-2614, 2551-2615, 2551-2616, 2551-2617, 2551-2618, 2551-2619, 2551-2620, 2551-2621, 2551-2622, 2551-2623, 2551-2624, 2551-2625, 2551-2626, 2551-2627, 2551-2628, 2551-2629, 2551-2630, 2551-2631, 2553-2570, 2553-2571, 2553-2572, 2553-2573, 2553-2574, 2553-2575, 2553-2576, 2553-2577, 2553-2578, 2553-2579, 2553-2580, 2553-2581, 2553-2582, 2553-2583, 2553-2584, 2553-2585, 2553-2586, 2553-2587, 2553-2588, 2553-2589, 2553-2590, 2553-2591, 2553-2592, 2553-2593, 2553-2594, 2553-2595, 2553-2596, 2553-2597, 2553-2598, 2553-2599, 2553-2600, 2553-2601, 2553-2602, 2553-2603, 2553-2604, 2553-2605, 2553-2606, 2553-2607, 2553-2608, 2553-2609, 2553-2610, 2553-2611, 2553-2612, 2553-2613, 2553-2614, 2553-2615, 2553-2616, 2553-2617, 2553-2618, 2553-2619, 2553-2620, 2553-2621, 2553-2622, 2553-2623, 2553-2624, 2553-2625, 2553-2626, 2553-2627, 2553-2628, 2553-2629, 2553-2630, 2553-2631, 2554-2573, 2554-2574, 2554-2575, 2554-2576, 2554-2577, 2554-2578, 2554-2579, 2554-2580, 2554-2581, 2554-2582, 2554-2583, 2554-2584, 2554-2585, 2554-2586, 2554-2587, 2554-2588, 2554-2589, 2554-2590, 2554-2591, 2554-2592, 2554-2593, 2554-2594, 2554-2595, 2554-2596, 2554-2597, 2554-2598, 2554-2599, 2554-2600, 2554-2601, 2554-2602, 2554-2603, 2554-2604, 2554-2605, 2554-2606, 2554-2607, 2554-2608, 2554-2609, 2554-2610, 2554-2611, 2554-

2612, 2554-2613, 2554-2614, 2554-2615, 2554-2616, 2554-2617, 2554-2618, 2554-2619, 2554-2620, 2554-2621, 2554-2622, 2554-2623, 2554-2624, 2554-2625, 2554-2626, 2554-2627, 2554-2628, 2554-2629, 2554-2630, 2554-2631, 2555-2572, 2555-2573, 2555-2574, 2555-2575, 2555-2576, 2555-2577, 2555-2578, 2555-2579, 2555-2580, 2555-2581, 2555-2582, 2555-2583, 2555-2584, 2555-2585, 2555-2586, 2555-2587, 2555-2588, 2555-2589, 2555-2590, 2555-2591, 2555-2592, 2555-2593, 2555-2594, 2555-2595, 2555-2596, 2555-2597, 2555-2598, 2555-2599, 2555-2600, 2555-2601, 2555-2602, 2555-2603, 2555-2604, 2555-2605, 2555-2606, 2555-2607, 2555-2608, 2555-2609, 2555-2610, 2555-2611, 2555-2612, 2555-2613, 2555-2614, 2555-2615, 2555-2616, 2555-2617, 2555-2618, 2555-2619, 2555-2620, 2555-2621, 2555-2622, 2555-2623, 2555-2624, 2555-2625, 2555-2626, 2555-2627, 2555-2628, 2555-2629, 2555-2630, 2555-2631, 2556-2573, 2556-2574, 2556-2575, 2556-2576, 2556-2577, 2556-2578, 2556-2579, 2556-2580, 2556-2581, 2556-2582, 2556-2583, 2556-2584, 2556-2585, 2556-2586, 2556-2587, 2556-2588, 2556-2589, 2556-2590, 2556-2591, 2556-2592, 2556-2593, 2556-2594, 2556-2595, 2556-2596, 2556-2597, 2556-2598, 2556-2599, 2556-2600, 2556-2601, 2556-2602, 2556-2603, 2556-2604, 2556-2605, 2556-2606, 2556-2607, 2556-2608, 2556-2609, 2556-2610, 2556-2611, 2556-2612, 2556-2613, 2556-2614, 2556-2615, 2556-2616, 2556-2617, 2556-2618, 2556-2619, 2556-2620, 2556-2621, 2556-2622, 2556-2623, 2556-2624, 2556-2625, 2556-2626, 2556-2627, 2556-2628, 2556-2629, 2556-2630, 2556-2631, 2557-2574, 2557-2575, 2557-2576, 2557-2577, 2557-2578, 2557-2579, 2557-2580, 2557-2581, 2557-2582, 2557-2583, 2557-2584, 2557-2585, 2557-2586, 2557-2587, 2557-2588, 2557-2589, 2557-2590, 2557-2591, 2557-2592, 2557-2593, 2557-2594, 2557-2595, 2557-2596, 2557-2597, 2557-2598, 2557-2599, 2557-2600, 2557-2601, 2557-2602, 2557-2603, 2557-2604, 2557-2605, 2557-2606, 2557-2607, 2557-2608, 2557-2609, 2557-2610, 2557-2611, 2557-2612, 2557-2613, 2557-2614, 2557-2615, 2557-2616, 2557-2617, 2557-2618, 2557-2619, 2557-2620, 2557-2621, 2557-2622, 2557-2623, 2557-2624, 2557-2625, 2557-2626, 2557-2627, 2557-2628, 2557-2629, 2557-2630, 2557-2631, 2558-2575, 2558-2576, 2558-2577, 2558-2578, 2558-2579, 2558-2580, 2558-2581, 2558-2582, 2558-2583, 2558-2584, 2558-2585, 2558-2586, 2558-2587, 2558-2588, 2558-2589, 2558-2590, 2558-2591, 2558-2592, 2558-2593, 2558-2594, 2558-2595, 2558-2596, 2558-2597, 2558-2598, 2558-2599, 2558-2600, 2558-2601, 2558-2602, 2558-2603, 2558-2604, 2558-2605, 2558-2606, 2558-2607, 2558-2608, 2558-2609, 2558-2610, 2558-2611, 2558-2612, 2558-2613, 2558-2614, 2558-2615, 2558-2616, 2558-2617, 2558-2618, 2558-2619, 2558-2620, 2558-2621, 2558-2622, 2558-2623, 2558-2624, 2558-2625, 2558-2626, 2558-2627, 2558-2628, 2558-2629, 2558-2630, 2558-2631, 2559-2576, 2559-2577, 2559-2578, 2559-2579, 2559-2580, 2559-2581, 2559-2582, 2559-2583, 2559-2584, 2559-2585, 2559-2586, 2559-2587, 2559-2588, 2559-2589, 2559-2590, 2559-2591, 2559-2592, 2559-2593, 2559-2594, 2559-2595, 2559-2596, 2559-2597, 2559-2598, 2559-2599, 2559-2600, 2559-2601, 2559-2602, 2559-2603, 2559-2604, 2559-2605, 2559-2606, 2559-2607, 2559-2608, 2559-2609, 2559-2610, 2559-2611, 2559-2612, 2559-2613, 2559-2614, 2559-2615, 2559-2616, 2559-2617, 2559-2618, 2559-2619, 2559-2620, 2559-2621, 2559-2622, 2559-2623, 2559-2624, 2559-2625, 2559-2626, 2559-2627, 2559-2628, 2559-2629, 2559-2630, 2559-2631, 2560-2577, 2560-2578, 2560-2579, 2560-2580, 2560-2581, 2560-

2582, 2560-2583, 2560-2584, 2560-2585, 2560-2586, 2560-2587, 2560-2588, 2560-2589, 2560-2590, 2560-2591, 2560-2592, 2560-2593, 2560-2594, 2560-2595, 2560-2596, 2560-2597, 2560-2598, 2560-2599, 2560-2600, 2560-2601, 2560-2602, 2560-2603, 2560-2604, 2560-2605, 2560-2606, 2560-2607, 2560-2608, 2560-2609, 2560-2610, 2560-2611, 2560-2612, 2560-2613, 2560-2614, 2560-2615, 2560-2616, 2560-2617, 2560-2618, 2560-2619, 2560-2620, 2560-2621, 2560-2622, 2560-2623, 2560-2624, 2560-2625, 2560-2626, 2560-2627, 2560-2628, 2560-2629, 2560-2630, 2560-2631, 2561-2578, 2561-2579, 2561-2580, 2561-2581, 2561-2582, 2561-2583, 2561-2584, 2561-2585, 2561-2586, 2561-2587, 2561-2588, 2561-2589, 2561-2590, 2561-2591, 2561-2592, 2561-2593, 2561-2594, 2561-2595, 2561-2596, 2561-2597, 2561-2598, 2561-2599, 2561-2600, 2561-2601, 2561-2602, 2561-2603, 2561-2604, 2561-2605, 2561-2606, 2561-2607, 2561-2608, 2561-2609, 2561-2610, 2561-2611, 2561-2612, 2561-2613, 2561-2614, 2561-2615, 2561-2616, 2561-2617, 2561-2618, 2561-2619, 2561-2620, 2561-2621, 2561-2622, 2561-2623, 2561-2624, 2561-2625, 2561-2626, 2561-2627, 2561-2628, 2561-2629, 2561-2630, 2561-2631, 2562-2577, 2562-2578, 2562-2579, 2562-2580, 2562-2581, 2562-2582, 2562-2583, 2562-2584, 2562-2585, 2562-2586, 2562-2587, 2562-2588, 2562-2589, 2562-2590, 2562-2591, 2562-2592, 2562-2593, 2562-2594, 2562-2595, 2562-2596, 2562-2597, 2562-2598, 2562-2599, 2562-2600, 2562-2601, 2562-2602, 2562-2603, 2562-2604, 2562-2605, 2562-2606, 2562-2607, 2562-2608, 2562-2609, 2562-2610, 2562-2611, 2562-2612, 2562-2613, 2562-2614, 2562-2615, 2562-2616, 2562-2617, 2562-2618, 2562-2619, 2562-2620, 2562-2621, 2562-2622, 2562-2623, 2562-2624, 2562-2625, 2562-2626, 2562-2627, 2562-2628, 2562-2629, 2562-2630, 2562-2631, 2563-2580, 2563-2581, 2563-2582, 2563-2583, 2563-2584, 2563-2585, 2563-2586, 2563-2587, 2563-2588, 2563-2589, 2563-2590, 2563-2591, 2563-2592, 2563-2593, 2563-2594, 2563-2595, 2563-2596, 2563-2597, 2563-2598, 2563-2599, 2563-2600, 2563-2601, 2563-2602, 2563-2603, 2563-2604, 2563-2605, 2563-2606, 2563-2607, 2563-2608, 2563-2609, 2563-2610, 2563-2611, 2563-2612, 2563-2613, 2563-2614, 2563-2615, 2563-2616, 2563-2617, 2563-2618, 2563-2619, 2563-2620, 2563-2621, 2563-2622, 2563-2623, 2563-2624, 2563-2625, 2563-2626, 2563-2627, 2563-2628, 2563-2629, 2563-2630, 2563-2631, 2564-2581, 2564-2582, 2564-2583, 2564-2584, 2564-2585, 2564-2586, 2564-2587, 2564-2588, 2564-2589, 2564-2590, 2564-2591, 2564-2592, 2564-2593, 2564-2594, 2564-2595, 2564-2596, 2564-2597, 2564-2598, 2564-2599, 2564-2600, 2564-2601, 2564-2602, 2564-2603, 2564-2604, 2564-2605, 2564-2606, 2564-2607, 2564-2608, 2564-2609, 2564-2610, 2564-2611, 2564-2612, 2564-2613, 2564-2614, 2564-2615, 2564-2616, 2564-2617, 2564-2618, 2564-2619, 2564-2620, 2564-2621, 2564-2622, 2564-2623, 2564-2624, 2564-2625, 2564-2626, 2564-2627, 2564-2628, 2564-2629, 2564-2630, 2564-2631, 2565-2584, 2565-2585, 2565-2586, 2565-2587, 2565-2588, 2565-2589, 2565-2590, 2565-2591, 2565-2592, 2565-2593, 2565-2594, 2565-2595, 2565-2596, 2565-2597, 2565-2598, 2565-2599, 2565-2600, 2565-2601, 2565-2602, 2565-2603, 2565-2604, 2565-2605, 2565-2606, 2565-2607, 2565-2608, 2565-2609, 2565-2610, 2565-2611, 2565-2612, 2565-2613, 2565-2614, 2565-2615, 2565-2616, 2565-2617, 2565-2618, 2565-2619, 2565-2620, 2565-2621, 2565-2622, 2565-2623, 2565-2624, 2565-2625, 2565-2626, 2565-2627, 2565-2628, 2565-2629, 2565-2630, 2565-2631, 2566-2583, 2566-2584, 2566-2585, 2566-2586, 2566-2587, 2566-

2588, 2566-2589, 2566-2590, 2566-2591, 2566-2592, 2566-2593, 2566-2594, 2566-2595, 2566-2596, 2566-2597, 2566-2598, 2566-2599, 2566-2600, 2566-2601, 2566-2602, 2566-2603, 2566-2604, 2566-2605, 2566-2606, 2566-2607, 2566-2608, 2566-2609, 2566-2610, 2566-2611, 2566-2612, 2566-2613, 2566-2614, 2566-2615, 2566-2616, 2566-2617, 2566-2618, 2566-2619, 2566-2620, 2566-2621, 2566-2622, 2566-2623, 2566-2624, 2566-2625, 2566-2626, 2566-2627, 2566-2628, 2566-2629, 2566-2630, 2566-2631, 2567-2584, 2567-2585, 2567-2586, 2567-2587, 2567-2588, 2567-2589, 2567-2590, 2567-2591, 2567-2592, 2567-2593, 2567-2594, 2567-2595, 2567-2596, 2567-2597, 2567-2598, 2567-2599, 2567-2600, 2567-2601, 2567-2602, 2567-2603, 2567-2604, 2567-2605, 2567-2606, 2567-2607, 2567-2608, 2567-2609, 2567-2610, 2567-2611, 2567-2612, 2567-2613, 2567-2614, 2567-2615, 2567-2616, 2567-2617, 2567-2618, 2567-2619, 2567-2620, 2567-2621, 2567-2622, 2567-2623, 2567-2624, 2567-2625, 2567-2626, 2567-2627, 2567-2628, 2567-2629, 2567-2630, 2567-2631, 2568-2585, 2568-2586, 2568-2587, 2568-2588, 2568-2589, 2568-2590, 2568-2591, 2568-2592, 2568-2593, 2568-2594, 2568-2595, 2568-2596, 2568-2597, 2568-2598, 2568-2599, 2568-2600, 2568-2601, 2568-2602, 2568-2603, 2568-2604, 2568-2605, 2568-2606, 2568-2607, 2568-2608, 2568-2609, 2568-2610, 2568-2611, 2568-2612, 2568-2613, 2568-2614, 2568-2615, 2568-2616, 2568-2617, 2568-2618, 2568-2619, 2568-2620, 2568-2621, 2568-2622, 2568-2623, 2568-2624, 2568-2625, 2568-2626, 2568-2627, 2568-2628, 2568-2629, 2568-2630, 2568-2631, 2569-2586, 2569-2587, 2569-2588, 2569-2589, 2569-2590, 2569-2591, 2569-2592, 2569-2593, 2569-2594, 2569-2595, 2569-2596, 2569-2597, 2569-2598, 2569-2599, 2569-2600, 2569-2601, 2569-2602, 2569-2603, 2569-2604, 2569-2605, 2569-2606, 2569-2607, 2569-2608, 2569-2609, 2569-2610, 2569-2611, 2569-2612, 2569-2613, 2569-2614, 2569-2615, 2569-2616, 2569-2617, 2569-2618, 2569-2619, 2569-2620, 2569-2621, 2569-2622, 2569-2623, 2569-2624, 2569-2625, 2569-2626, 2569-2627, 2569-2628, 2569-2629, 2569-2630, 2569-2631, 2569-2586, 2569-2587, 2569-2588, 2569-2589, 2569-2590, 2569-2591, 2569-2592, 2569-2593, 2569-2594, 2569-2595, 2569-2596, 2569-2597, 2569-2598, 2569-2599, 2569-2600, 2569-2601, 2569-2602, 2569-2603, 2569-2604, 2569-2605, 2569-2606, 2569-2607, 2569-2608, 2569-2609, 2569-2610, 2569-2611, 2569-2612, 2569-2613, 2569-2614, 2569-2615, 2569-2616, 2569-2617, 2569-2618, 2569-2619, 2569-2620, 2569-2621, 2569-2622, 2569-2623, 2569-2624, 2569-2625, 2569-2626, 2569-2627, 2569-2628, 2569-2629, 2569-2630, 2569-2631, 2571-2588, 2571-2589, 2571-2590, 2571-2591, 2571-2592, 2571-2593, 2571-2594, 2571-2595, 2571-2596, 2571-2597, 2571-2598, 2571-2599, 2571-2600, 2571-2601, 2571-2602, 2571-2603, 2571-2604, 2571-2605, 2571-2606, 2571-2607, 2571-2608, 2571-2609, 2571-2610, 2571-2611, 2571-2612, 2571-2613, 2571-2614, 2571-2615, 2571-2616, 2571-2617, 2571-2618, 2571-2619, 2571-2620, 2571-2621, 2571-2622, 2571-2623, 2571-2624, 2571-2625, 2571-2626, 2571-2627, 2571-2628, 2571-2629, 2571-2630, 2571-2631, 2572-2589, 2572-2590, 2572-2591, 2572-2592, 2572-2593, 2572-2594, 2572-2595, 2572-2596, 2572-2597, 2572-2598, 2572-2599, 2572-2600, 2572-2601, 2572-2602, 2572-2603, 2572-2604, 2572-2605, 2572-2606, 2572-2607, 2572-2608, 2572-2609, 2572-2610, 2572-2611, 2572-2612, 2572-2613, 2572-2614, 2572-2615, 2572-2616, 2572-2617, 2572-2618, 2572-2619, 2572-2620, 2572-2621, 2572-2622, 2572-2623, 2572-2624, 2572-2625, 2572-2626, 2572-2627, 2572-2628, 2572-

2629, 2572-2630, 2572-2631, 2573-2590, 2573-2591, 2573-2592, 2573-2593, 2573-2594, 2573-2595, 2573-2596, 2573-2597, 2573-2598, 2573-2599, 2573-2600, 2573-2601, 2573-2602, 2573-2603, 2573-2604, 2573-2605, 2573-2606, 2573-2607, 2573-2608, 2573-2609, 2573-2610, 2573-2611, 2573-2612, 2573-2613, 2573-2614, 2573-2615, 2573-2616, 2573-2617, 2573-2618, 2573-2619, 2573-2620, 2573-2621, 2573-2622, 2573-2623, 2573-2624, 2573-2625, 2573-2626, 2573-2627, 2573-2628, 2573-2629, 2573-2630, 2573-2631, 2574-2591, 2574-2592, 2574-2593, 2574-2594, 2574-2595, 2574-2596, 2574-2597, 2574-2598, 2574-2599, 2574-2600, 2574-2601, 2574-2602, 2574-2603, 2574-2604, 2574-2605, 2574-2606, 2574-2607, 2574-2608, 2574-2609, 2574-2610, 2574-2611, 2574-2612, 2574-2613, 2574-2614, 2574-2615, 2574-2616, 2574-2617, 2574-2618, 2574-2619, 2574-2620, 2574-2621, 2574-2622, 2574-2623, 2574-2624, 2574-2625, 2574-2626, 2574-2627, 2574-2628, 2574-2629, 2574-2630, 2574-2631, 2575-2592, 2575-2593, 2575-2594, 2575-2595, 2575-2596, 2575-2597, 2575-2598, 2575-2599, 2575-2600, 2575-2601, 2575-2602, 2575-2603, 2575-2604, 2575-2605, 2575-2606, 2575-2607, 2575-2608, 2575-2609, 2575-2610, 2575-2611, 2575-2612, 2575-2613, 2575-2614, 2575-2615, 2575-2616, 2575-2617, 2575-2618, 2575-2619, 2575-2620, 2575-2621, 2575-2622, 2575-2623, 2575-2624, 2575-2625, 2575-2626, 2575-2627, 2575-2628, 2575-2629, 2575-2630, 2575-2631, 2576-2593, 2576-2594, 2576-2595, 2576-2596, 2576-2597, 2576-2598, 2576-2599, 2576-2600, 2576-2601, 2576-2602, 2576-2603, 2576-2604, 2576-2605, 2576-2606, 2576-2607, 2576-2608, 2576-2609, 2576-2610, 2576-2611, 2576-2612, 2576-2613, 2576-2614, 2576-2615, 2576-2616, 2576-2617, 2576-2618, 2576-2619, 2576-2620, 2576-2621, 2576-2622, 2576-2623, 2576-2624, 2576-2625, 2576-2626, 2576-2627, 2576-2628, 2576-2629, 2576-2630, 2576-2631, 2577-2594, 2577-2595, 2577-2596, 2577-2597, 2577-2598, 2577-2599, 2577-2600, 2577-2601, 2577-2602, 2577-2603, 2577-2604, 2577-2605, 2577-2606, 2577-2607, 2577-2608, 2577-2609, 2577-2610, 2577-2611, 2577-2612, 2577-2613, 2577-2614, 2577-2615, 2577-2616, 2577-2617, 2577-2618, 2577-2619, 2577-2620, 2577-2621, 2577-2622, 2577-2623, 2577-2624, 2577-2625, 2577-2626, 2577-2627, 2577-2628, 2577-2629, 2577-2630, 2577-2631, 2578-2597, 2578-2598, 2578-2599, 2578-2600, 2578-2601, 2578-2602, 2578-2603, 2578-2604, 2578-2605, 2578-2606, 2578-2607, 2578-2608, 2578-2609, 2578-2610, 2578-2611, 2578-2612, 2578-2613, 2578-2614, 2578-2615, 2578-2616, 2578-2617, 2578-2618, 2578-2619, 2578-2620, 2578-2621, 2578-2622, 2578-2623, 2578-2624, 2578-2625, 2578-2626, 2578-2627, 2578-2628, 2578-2629, 2578-2630, 2578-2631, 2579-2598, 2579-2599, 2579-2600, 2579-2601, 2579-2602, 2579-2603, 2579-2604, 2579-2605, 2579-2606, 2579-2607, 2579-2608, 2579-2609, 2579-2610, 2579-2611, 2579-2612, 2579-2613, 2579-2614, 2579-2615, 2579-2616, 2579-2617, 2579-2618, 2579-2619, 2579-2620, 2579-2621, 2579-2622, 2579-2623, 2579-2624, 2579-2625, 2579-2626, 2579-2627, 2579-2628, 2579-2629, 2579-2630, 2579-2631, 2580-2598, 2580-2599, 2580-2600, 2580-2601, 2580-2602, 2580-2603, 2580-2604, 2580-2605, 2580-2606, 2580-2607, 2580-2608, 2580-2609, 2580-2610, 2580-2611, 2580-2612, 2580-2613, 2580-2614, 2580-2615, 2580-2616, 2580-2617, 2580-2618, 2580-2619, 2580-2620, 2580-2621, 2580-2622, 2580-2623, 2580-2624, 2580-2625, 2580-2626, 2580-2627, 2580-2628, 2580-2629, 2580-2630, 2580-2631, 2581-2597, 2581-2598, 2581-2599, 2581-2600, 2581-2601, 2581-2602, 2581-2603, 2581-2604, 2581-2605, 2581-

2606, 2581-2607, 2581-2608, 2581-2609, 2581-2610, 2581-2611, 2581-2612, 2581-2613, 2581-2614, 2581-2615, 2581-2616, 2581-2617, 2581-2618, 2581-2619, 2581-2620, 2581-2621, 2581-2622, 2581-2623, 2581-2624, 2581-2625, 2581-2626, 2581-2627, 2581-2628, 2581-2629, 2581-2630, 2581-2631, 2582-2600, 2582-2601, 2582-2602, 2582-2603, 2582-2604, 2582-2605, 2582-2606, 2582-2607, 2582-2608, 2582-2609, 2582-2610, 2582-2611, 2582-2612, 2582-2613, 2582-2614, 2582-2615, 2582-2616, 2582-2617, 2582-2618, 2582-2619, 2582-2620, 2582-2621, 2582-2622, 2582-2623, 2582-2624, 2582-2625, 2582-2626, 2582-2627, 2582-2628, 2582-2629, 2582-2630, 2582-2631, 2583-2601, 2583-2602, 2583-2603, 2583-2604, 2583-2605, 2583-2606, 2583-2607, 2583-2608, 2583-2609, 2583-2610, 2583-2611, 2583-2612, 2583-2613, 2583-2614, 2583-2615, 2583-2616, 2583-2617, 2583-2618, 2583-2619, 2583-2620, 2583-2621, 2583-2622, 2583-2623, 2583-2624, 2583-2625, 2583-2626, 2583-2627, 2583-2628, 2583-2629, 2583-2630, 2583-2631, 2585-2603, 2585-2604, 2585-2605, 2585-2606, 2585-2607, 2585-2608, 2585-2609, 2585-2610, 2585-2611, 2585-2612, 2585-2613, 2585-2614, 2585-2615, 2585-2616, 2585-2617, 2585-2618, 2585-2619, 2585-2620, 2585-2621, 2585-2622, 2585-2623, 2585-2624, 2585-2625, 2585-2626, 2585-2627, 2585-2628, 2585-2629, 2585-2630, 2585-2631, 2586-2604, 2586-2605, 2586-2606, 2586-2607, 2586-2608, 2586-2609, 2586-2610, 2586-2611, 2586-2612, 2586-2613, 2586-2614, 2586-2615, 2586-2616, 2586-2617, 2586-2618, 2586-2619, 2586-2620, 2586-2621, 2586-2622, 2586-2623, 2586-2624, 2586-2625, 2586-2626, 2586-2627, 2586-2628, 2586-2629, 2586-2630, 2586-2631, 2587-2605, 2587-2606, 2587-2607, 2587-2608, 2587-2609, 2587-2610, 2587-2611, 2587-2612, 2587-2613, 2587-2614, 2587-2615, 2587-2616, 2587-2617, 2587-2618, 2587-2619, 2587-2620, 2587-2621, 2587-2622, 2587-2623, 2587-2624, 2587-2625, 2587-2626, 2587-2627, 2587-2628, 2587-2629, 2587-2630, 2587-2631, 2588-2606, 2588-2607, 2588-2608, 2588-2609, 2588-2610, 2588-2611, 2588-2612, 2588-2613, 2588-2614, 2588-2615, 2588-2616, 2588-2617, 2588-2618, 2588-2619, 2588-2620, 2588-2621, 2588-2622, 2588-2623, 2588-2624, 2588-2625, 2588-2626, 2588-2627, 2588-2628, 2588-2629, 2588-2630, 2588-2631, 2589-2607, 2589-2608, 2589-2609, 2589-2610, 2589-2611, 2589-2612, 2589-2613, 2589-2614, 2589-2615, 2589-2616, 2589-2617, 2589-2618, 2589-2619, 2589-2620, 2589-2621, 2589-2622, 2589-2623, 2589-2624, 2589-2625, 2589-2626, 2589-2627, 2589-2628, 2589-2629, 2589-2630, 2589-2631, 2590-2606, 2590-2607, 2590-2608, 2590-2609, 2590-2610, 2590-2611, 2590-2612, 2590-2613, 2590-2614, 2590-2615, 2590-2616, 2590-2617, 2590-2618, 2590-2619, 2590-2620, 2590-2621, 2590-2622, 2590-2623, 2590-2624, 2590-2625, 2590-2626, 2590-2627, 2590-2628, 2590-2629, 2590-2630, 2590-2631, 2591-2610, 2591-2611, 2591-2612, 2591-2613, 2591-2614, 2591-2615, 2591-2616, 2591-2617, 2591-2618, 2591-2619, 2591-2620, 2591-2621, 2591-2622, 2591-2623, 2591-2624, 2591-2625, 2591-2626, 2591-2627, 2591-2628, 2591-2629, 2591-2630, 2591-2631, 2592-2611, 2592-2612, 2592-2613, 2592-2614, 2592-2615, 2592-2616, 2592-2617, 2592-2618, 2592-2619, 2592-2620, 2592-2621, 2592-2622, 2592-2623, 2592-2624, 2592-2625, 2592-2626, 2592-2627, 2592-2628, 2592-2629, 2592-2630, 2592-2631, 2593-2608, 2593-2612, 2593-2613, 2593-2614, 2593-2615, 2593-2616, 2593-2617, 2593-2618, 2593-2619, 2593-2620, 2593-2621, 2593-2622, 2593-2623, 2593-2624, 2593-2625, 2593-2626, 2593-2627, 2593-2628, 2593-2629, 2593-2630, 2593-2631, 2594-2612, 2594-

2613, 2594-2614, 2594-2615, 2594-2616, 2594-2617, 2594-2618, 2594-2619, 2594-2620, 2594-2621, 2594-2622, 2594-2623, 2594-2624, 2594-2625, 2594-2626, 2594-2627, 2594-2628, 2594-2629, 2594-2630, 2594-2631, 2595-2611, 2595-2612, 2595-2613, 2595-2614, 2595-2615, 2595-2616, 2595-2617, 2595-2618, 2595-2619, 2595-2620, 2595-2621, 2595-2622, 2595-2623, 2595-2624, 2595-2625, 2595-2626, 2595-2627, 2595-2628, 2595-2629, 2595-2630, 2595-2631, 2596-2614, 2596-2615, 2596-2616, 2596-2617, 2596-2618, 2596-2619, 2596-2620, 2596-2621, 2596-2622, 2596-2623, 2596-2624, 2596-2625, 2596-2626, 2596-2627, 2596-2628, 2596-2629, 2596-2630, 2596-2631, 2597-2612, 2597-2613, 2597-2614, 2597-2615, 2597-2616, 2597-2617, 2597-2618, 2597-2619, 2597-2620, 2597-2621, 2597-2622, 2597-2623, 2597-2624, 2597-2625, 2597-2626, 2597-2627, 2597-2628, 2597-2629, 2597-2630, 2597-2631, 2598-2613, 2598-2614, 2598-2615, 2598-2616, 2598-2617, 2598-2618, 2598-2619, 2598-2620, 2598-2621, 2598-2622, 2598-2623, 2598-2624, 2598-2625, 2598-2626, 2598-2627, 2598-2628, 2598-2629, 2598-2630, 2598-2631, 2599-2614, 2599-2615, 2599-2616, 2599-2617, 2599-2618, 2599-2619, 2599-2620, 2599-2621, 2599-2622, 2599-2623, 2599-2624, 2599-2625, 2599-2626, 2599-2627, 2599-2628, 2599-2629, 2599-2630, 2599-2631, 2600-2615, 2600-2616, 2600-2617, 2600-2618, 2600-2619, 2600-2620, 2600-2621, 2600-2622, 2600-2623, 2600-2624, 2600-2625, 2600-2626, 2600-2627, 2600-2628, 2600-2629, 2600-2630, 2600-2631, 2601-2616, 2601-2617, 2601-2618, 2601-2619, 2601-2620, 2601-2621, 2601-2622, 2601-2623, 2601-2624, 2601-2625, 2601-2626, 2601-2627, 2601-2628, 2601-2629, 2601-2630, 2601-2631, 2602-2618, 2602-2619, 2602-2620, 2602-2621, 2602-2622, 2602-2623, 2602-2624, 2602-2625, 2602-2626, 2602-2627, 2602-2628, 2602-2629, 2602-2630, 2602-2631, 2603-2620, 2603-2621, 2603-2622, 2603-2623, 2603-2624, 2603-2625, 2603-2626, 2603-2627, 2603-2628, 2603-2629, 2603-2630, 2603-2631, 2604-2619, 2604-2620, 2604-2621, 2604-2622, 2604-2623, 2604-2624, 2604-2625, 2604-2626, 2604-2627, 2604-2628, 2604-2629, 2604-2630, 2604-2631, 2605-2620, 2605-2621, 2605-2622, 2605-2623, 2605-2624, 2605-2625, 2605-2626, 2605-2627, 2605-2628, 2605-2629, 2605-2630, 2605-2631, 2606-2621, 2606-2622, 2606-2623, 2606-2624, 2606-2625, 2606-2626, 2606-2627, 2606-2628, 2606-2629, 2606-2630, 2606-2631, 2607-2622, 2607-2623, 2607-2624, 2607-2625, 2607-2626, 2607-2627, 2607-2628, 2607-2629, 2607-2630, 2607-2631, 2608-2623, 2608-2624, 2608-2625, 2608-2626, 2608-2627, 2608-2628, 2608-2629, 2608-2630, 2608-2631, 2609-2624, 2609-2625, 2609-2626, 2609-2627, 2609-2628, 2609-2629, 2609-2630, 2609-2631, 2610-2625, 2610-2626, 2610-2627, 2610-2628, 2610-2629, 2610-2630, 2610-2631, 2611-2626, 2611-2627, 2611-2628, 2611-2629, 2611-2630, 2611-2631, 2612-2627, 2612-2628, 2612-2629, 2612-2630, 2612-2631, 2613-2628, 2613-2629, 2613-2630, 2613-2631, 2614-2629, 2614-2630, 2614-2631, 2615-2630, 2615-2631, or 2616-2631 of a CFB nucleic acid having the nucleobase sequence of SEQ ID NO: 1, and wherein the nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID NO:1.

8. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides complementary within nucleotides 2193-

2212, 2195-2210, 2457-2476, 2571-2590, 2584-2603, 2588-2607, 2592-2611, 2594-2613, 2597-2616, 2600-2619, or 2596-2611 of SEQ ID NO: 1.

9. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 8 to 80 linked nucleosides having a nucleobase sequence comprising any one of SEQ ID NO: 198, 228, 237, 440, 444, 448, 450, 453, 455, 549, and 598.

10. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide has a nucleobase sequence consisting of any one of SEQ ID NO: 198, 228, 237, 440, 444, 448, 450, 453, 455, 549, and 598.

11. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 6-808.

12. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 9 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 6-808.

13. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 10 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 6-808.

14. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 11 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 6-808.

15. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 6-808.

16. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 6-808.

17. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of the nucleobase sequence of any one of SEQ ID NOs: 6-808.

18. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide has a nucleobase sequence comprising at least an 8 nucleobase portion of any one of SEQ ID NOs: 84, 238, 239, 317, 412, 413, 420, 421, 426, 434, 436, 437, 438, 439, 440, 442, 443, 444, 445, 446, 448, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 464, 465, 472, 473, 514, 515, 542, 543, 544, 545, 546, 551, 553, 555, 556, 599, 600, 601, 602, 610, 616, 617, 618, 662, 666, 670, 676, 677, 678, 688, 689, 713, 723, 729, 730, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 755, 756, 768, 783, 793, 833, and 867.

19. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides having a nucleobase sequence comprising any one of SEQ ID NOs: 198, 228, 237, 440, 444, 448, 450, 453, 455, 549, and 598, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides; and

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

20. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 198, 228, 237, 440, 444, 448, 450, 453, or 455, wherein the modified oligonucleotide comprises

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides; and

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each internucleoside linkage is a phosphorothioate linkage and wherein each cytosine is a 5-methylcytosine.

21. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 16 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 598, wherein the modified oligonucleotide comprises

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the 5' wing segment comprises a 2'-O-methoxyethyl sugar, 2'-O-methoxyethyl sugar, and cEt sugar in the 5' to 3' direction; wherein the 3' wing segment comprises a cEt sugar, cEt sugar, and 2'-O-methoxyethyl sugar in the 5' to 3' direction; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

22. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 16 linked nucleosides having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 549, wherein the modified oligonucleotide comprises

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3’ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment; wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

23. The compound of any one of claims 1-22, wherein the oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to SEQ ID NO: 1 or 2.

24. The compound of any one of claims 1-23, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar, or at least one modified nucleobase.

25. The compound of claim 24, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

26. The compound of claim 25, wherein the modified oligonucleotide comprises at least 1 phosphodiester internucleoside linkage.

27. The compound of claim 25, wherein the modified oligonucleotide comprises at least 2 phosphodiester internucleoside linkage.

28. The compound of claim 25, wherein the modified oligonucleotide comprises at least 3 phosphodiester internucleoside linkage.

29. The compound of claim 25, wherein the modified oligonucleotide comprises at least 4 phosphodiester internucleoside linkage.

30. The compound of claim 25, wherein the modified oligonucleotide comprises at least 5 phosphodiester internucleoside linkage.

31. The compound of claim 25, wherein the modified oligonucleotide comprises at least 6 phosphodiester internucleoside linkage.

32. The compound of claim 25, wherein the modified oligonucleotide comprises at least 7 phosphodiester internucleoside linkage.

33. The compound of any of claims 26-32, wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.

34. The compound of claim 25, wherein each internucleoside linkage of the modified oligonucleotide comprises a phosphorothioate internucleoside linkage.

35. The compound of any one of claims 24-34, wherein the modified sugar is a bicyclic sugar.

36. The compound of claim 35, wherein the bicyclic sugar is selected from the group consisting of: 4'-(CH_2)-O-2' (LNA); 4'-$(CH_2)_2$-O-2' (ENA); and 4'-$CH(CH_3)$-O-2' (cEt).

37. The compound of any one of claims 24-34, wherein the modified sugar is 2’-O-methoxyethyl.

38. The compound of any one of claims 24-37, wherein the modified nucleobase is a 5-methylcytosine.

39. The compound of any one of claims 1-38, wherein the modified oligonucleotide comprises:

(a) a gap segment consisting of linked deoxynucleosides;

(b) a 5' wing segment consisting of linked nucleosides; and

(c) a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned immediately adjacent to and between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

40. The compound of any one of claims 1-39, wherein the compound is single-stranded.

41. The compound of any one of claims 1-39, wherein the compound is double-stranded.

42. The compound of any one of claims 1-41, wherein the compound comprises ribonucleotides.

43. The compound of any one of claims 1-41, wherein the compound comprises deoxyribonucleotides.

44. The compound of any one of claims 1-43, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides.

45. The compound of any one of claims 1-43, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides.

46. The compound of any one of claims 1-43, wherein the modified oligonucleotide consists of 15 to 30 linked nucleosides.

47. A compound consisting of ISIS 532770, ISIS 532800, ISIS 532809, ISIS 588540, ISIS 588544, ISIS 588548, ISIS 588550, ISIS 588553, ISIS 588555, ISIS 588848, or ISIS 594430, and a conjugate group.

48. The compound of any of claims 1 to 47, wherein the conjugate group is linked to the modified oligonucleotide at the 5' end of the modified oligonucleotide.

49. The compound of any of claims 1 to 47, wherein the conjugate group is linked to the modified oligonucleotide at the 3' end of the modified oligonucleotide.

50. The compound of any of claims 1-49, wherein the conjugate group comprises exactly one ligand.

51. The compound of any of claims 1-49, wherein the conjugate group comprises exactly two ligands.


52. The compound of any of claims 1-49, wherein the conjugate group comprises three or more ligands.

53. The compound of any of claims 1-49, wherein the conjugate group comprises exactly three ligands.


54. The compound of any of claims 50-53, wherein each ligand is selected from among: a polysaccharide, modified polysaccharide, mannose, galactose, a mannose derivative, a galactose derivative, D-mannopyranose, L-Mannopyranose, D-Arabinose, L-Galactose, D-xylofuranose, L-xylofuranose, D-glucose, L-glucose, D-Galactose, L-Galactose, α-D-Mannofuranose, β-D-Mannofuranose, α-D-Mannopyranose, β-D-Mannopyranose, α-D-Glucopyranose, β-D-Glucopyranose, α-D-Glucofuranose, β-D-Glucofuranose, α-D-fructofuranose, α-D-fructopyranose, α-D-Galactopyranose, β -D-Galactopyranose, α-D-Galactofuranose, β -D-Galactofuranose, glucosamine, sialic acid, α-D-galactosamine, N-Acetylgalactosamine, 2-Amino-3-*O*-[(*R*)-1-carboxyethyl]-2-deoxy-β-D-glucopyranose, 2-Deoxy-2-methylamino-L-glucopyranose, 4,6-Dideoxy-4-formamido-2,3-di-*O*-methyl-D-mannopyranose, 2-Deoxy-2-sulfoamino-D-glucopyranose, *N*-Glycoloyl-α-neuraminic acid, 5-thio-β-D-glucopyranose, methyl 2,3,4-tri-*O*-acetyl-1-thio-6-*O*-trityl-α-D-glucopyranoside, 4-Thio-β-D-galactopyranose, ethyl 3,4,6,7-tetra-*O*-acetyl-2-deoxy-1,5-dithio-α-D-*gluco*-heptopyranoside, 2,5-Anhydro-D-allononitrile, ribose, D-ribose, D-4-thioribose, L-ribose, L-4-thioribose.

55. The compound of claim 54, wherein each ligand is N-acetyl galactosamine.


56. The compound of any of claims 1 to 55, wherein the conjugate group comprises:




57. The compound of any of claims 1 to 55, wherein the conjugate group comprises:




58. The compound of any of claims 1 to 55, wherein the conjugate group comprises:



59. The compound of any of claims 1 to 55, wherein the conjugate group comprises:




60. The compound of any of claims 1 to 55, wherein the conjugate group comprises:



61. The compound of any of claims 49 to 60, wherein the conjugate group comprises at least one phosphorus linking group or neutral linking group.


62. The compound of any of claims 1 to 61, wherein the conjugate group comprises a structure selected from among:



wherein n is from 1 to 12; and

wherein m is from 1 to 12.

63. The compound of any of claims 1 to 62, wherein the conjugate group has a tether having a structure selected from among:



wherein L is either a phosphorus linking group or a neutral linking group;


Z_1 is $C(=O)O\text{-}R_2$;

Z_2 is H, C_1-C_6 alkyl or substituted C_1-C_6 alky;

R_2 is H, C_1-C_6 alkyl or substituted C_1-C_6 alky; and

each m_1 is, independently, from 0 to 20 wherein at least one m_1 is greater than 0 for each tether.


64. The compound of claim 63, wherein conjugate group has a tether having a structure selected from among:



wherein Z_2 is H or CH_3; and

each m_1 is, independently, from 0 to 20 wherein at least one m_1 is greater than 0 for each tether.

65. The compound of any of claims 1 to 64, wherein the conjugate group has tether having a structure selected from among:




wherein n is from 1 to 12; and

wherein m is from 1 to 12.

66. The compound of any of claims 1 to 65, wherein the conjugate group is covalently attached to the modified oligonucleotide.

67. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;

B is the cleavable moiety

C is the conjugate linker


D is the branching group

each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

68. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein:

A is the modified oligonucleotide;

B is the cleavable moiety

C is the conjugate linker

D is the branching group


each E is a tether;

each F is a ligand;

each n is independently 0 or 1; and

q is an integer between 1 and 5.

69. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;

B is the cleavable moiety;


C is the conjugate linker;

each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

70. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;

C is the conjugate linker;


D is the branching group;

each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

71. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;


C is the conjugate linker;

each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

72. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;

B is the cleavable moiety;


D is the branching group;

each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

73. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;


B is the cleavable moiety;

each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

74. The compound of any of claims 1 to 66, wherein the compound has a structure represented by the formula:



wherein

A is the modified oligonucleotide;














D is the branching group;







each E is a tether;

each F is a ligand; and

q is an integer between 1 and 5.

75. The compound of any of claims 1 to 74, wherein the conjugate linker has a structure selected from among:


;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;






















and

.


wherein each L is, independently, a phosphorus linking group or a neutral linking group; and

each n is, independently, from 1 to 20.


76. The compound of any of claims 1 to 74, wherein the conjugate linker has a structure selected from among:


;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

and

.


77. The compound of any of claims 1 to 74, wherein the conjugate linker has the followingstructure:




78. The compound of any of claims 1 to 74, wherein the conjugate linker has a structure selected from among:



79. The compound of any of claims 1 to 74, wherein the conjugate linker has a structure selected from among:



80. The compound of any of claims 1 to 74, wherein the conjugate linker has a structure selected from among:



81. The compound of any of claims 1 to 80, wherein the conjugate linker comprises a pyrrolidine.

82. The compound of any of claims 1 to 80, wherein the conjugate linker does not comprise a pyrrolidine.

83. The compound of any of claims 1 to 82, wherein the conjugate linker comprises PEG.

84. The compound of any of claims 1 to 83, wherein the conjugate linker comprises an amide.

85. The compound of any of claims 1 to 84, wherein the conjugate linker comprises at least two amides.

86. The compound of any of claims 1 to 83, wherein the conjugate linker does not comprise an amide.

87. The compound of any of claims 1 to 86, wherein the conjugate linker comprises a polyamide.

88. The compound of any of claims 1 to 87, wherein the conjugate linker comprises an amine.

89. The compound of any of claims 1 to 88, wherein the conjugate linker comprises one or more disulfide bonds.

90. The compound of any of claims 1 to 89, wherein the conjugate linker comprises a protein binding moiety.


91. The compound of claim 90, wherein the protein binding moiety comprises a lipid.

92. The compound of claim 90, wherein the protein binding moiety is selected from among: cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine), a vitamin (e.g., folate, vitamin A, vitamin E, biotin, pyridoxal), a peptide, a carbohydrate (e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide,

polysaccharide), an endosomolytic component, a steroid (e.g., uvaol, hecigenin, diosgenin), a terpene (e.g., triterpene, e.g., sarsasapogenin, friedelin, epifriedelanol derivatized lithocholic acid), or a cationic lipid.

93. The compound of claim 90, wherein the protein binding moiety is selected from among: a C16 to C22 long chain saturated or unsaturated fatty acid, cholesterol, cholic acid, vitamin E, adamantane or 1-pentafluoropropyl.


94. The compound of any of claims 1 to 93, wherein the conjugate linker has a structure selected from among:



; and


wherein each n is, independently, is from 1 to 20; and p is from 1 to 6.

95. The compound of any of claims 1 to 94, wherein the conjugate linker has a structure selected from among:




wherein each n is, independently, from 1 to 20.

96. The compound of any of claims 1 to 94, wherein the conjugate linker has a structure selected from among:




97. The compound of any of claims 1 to 94, wherein the conjugate linker has a structure selected from among:




wherein n is from 1 to 20.

98. The compound of any of claims 1 to 94, wherein the conjugate linker has a structure selected from among:




99. The compound of any of claims 1 to 94, wherein the conjugate linker has a structure selected from among:




wherein each n is independently, 0, 1, 2, 3, 4, 5, 6, or 7.

100. The compound of any of claims 1 to 94, wherein the conjugate linker has the following structure:




101. The compound of any of claims 1 to 100, wherein the branching group has one of the following structures:



wherein each A_1 is independently, O, S, C=O or NH; and

each n is, independently, from 1 to 20.


102. The compound of any of claims 1 to 100, wherein the branching group has one of the following structures:



wherein each A_1 is independently, O, S, C=O or NH; and


each n is, independently, from 1 to 20.

103. The compound of any of claims 1 to 100, wherein the branching group has the following structure:




.

104. The compound of any of claims 1 to 100, wherein the branching group has the following structure:




.

105. The compound of any of claims 1 to 100, wherein the branching group has the following structure:



.


106. The compound of any of claims 1 to 100, wherein the branching group has the following structure:



.

107. The compound of any of claims 1 to 100, wherein the branching group comprises an ether.

108. The compound of any of claims 1 to 100, wherein the branching group has the following structure:









; and

each n is, independently, from 1 to 20; and


m is from 2 to 6.

109. The compound of any of claims 1 to 100, wherein the branching group has the following structure:





;

;


;

;

; and



.

110. The compound of any of claims 1 to 100, wherein the branching group has the following structure:


.

111. The compound of any of claims 1 to 100, wherein the branching group comprises:







,

,

,


, or

;



wherein each j is an integer from 1 to 3; and

wherein each n is an integer from 1 to 20.

112. The compound of any of claims 1 to 100, wherein the branching group comprises:


,

,

,

,
or

.

113. The compound of any of claims 1 to 112, wherein each tether is selected from among:


and


wherein L is selected from a phosphorus linking group and a neutral linking group;



Z_1 is C(=O)O-R_2;

Z_2 is H, C_1-C_6 alkyl or substituted C_1-C_6 alky;

R_2 is H, C_1-C_6 alkyl or substituted C_1-C_6 alky; and

each m_1 is, independently, from 0 to 20 wherein at least one m_1 is greater than 0 for each tether.



114. The compound of any of claims 1 to 112, wherein each tether is selected from among:



and


wherein Z_2 is H or CH_3; and

each m_2 is, independently, from 0 to 20 wherein at least one m_2 is greater than 0 for each tether.

115. The compound of any of claims 1 to 112, wherein each tether is selected from among:


;

;


;

wherein n is from 1 to 12; and

wherein m is from 1 to 12.

116. The compound of any of claims 1 to 112, wherein at least one tether comprises ethylene glycol.

117. The compound of any of claims 1 to 116, wherein at least one tether comprises an amide.













118. The compound of any of claims 1 to 117, wherein at least one tether comprises a polyamide.

119. The compound of any of claims 1 to 118, wherein at least one tether comprises an amine.

120. The compound of any of claims 1 to 119, wherein at least two tethers are different from one another.




121. The compound of any of claims 1 to 120, wherein all of the tethers are the same as one another.





122. The compound of any of claims 1 to 121, wherein each tether is selected from among:


;

;

;

;

;

;

;

;

;

;

; ; and



wherein each n is, independently, from 1 to 20; and
each p is from 1 to about 6.

123. The compound of any of claims 1 to 122, wherein each tether is selected from among:


;

;

;



;

;

; and

.

124. The compound of any of claims 1 to 123, wherein each tether has the following structure:





wherein each n is, independently, from 1 to 20.


125. The compound of any of claims 1 to 124, wherein each tether has the following structure:


.

126. The compound of any of claims 1 to 125, wherein the tether has a structure selected from among:


, or

; wherein each n is independently, 0, 1, 2, 3, 4, 5, 6, or 7.

127. The compound of claim 126, wherein the tether has the structure:



.

128. The compound of claim 126, wherein n is 3.


129. The compound of any of claims 1 to 128, wherein the ligand is galactose.

130. The compound of any of claims 1 to 128, wherein the ligand is mannose-6-phosphate.

131. The compound of any of claims 1 to 128, wherein each ligand is selected from among:




and




wherein each R_1 is selected from OH and NHCOOH.


132. The compound of any of claims 1 to 128, wherein each ligand is selected from among:




;




;




;




;




;



;




; and




.

133. The compound of any of claims 1 to 128, wherein each ligand has the following structure:




134. The conjugated antisense compound of any of claims 124 to 127, wherein each ligand has the following structure:




135. The compound of any of claims 1 to 134, wherein the conjugate group comprises a cell-targeting moiety.

136. The compound of claim 135, wherein the conjugate group comprises a cell-targeting moiety having the following structure:




wherein each n is, independently, from 1 to 20.

137. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




138. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




wherein each n is, independently, from 1 to 20.


139. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




140. The compound of claim 135, wherein the cell-targeting moiety comprises:




141. The compound of claim 135, wherein the cell-targeting moiety comprises:




142. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




143. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




144. The compound of claim 135, wherein the cell-targeting moiety comprises:




145. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




146. The compound of claim 135, wherein the cell-targeting moiety comprises:




147. The compound of claim 135, wherein the cell-targeting moiety comprises:




148. The compound of claim 135, wherein the cell-targeting moiety comprises:




149. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




150. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




151. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




152. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




153. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




154. The compound of claim 135, wherein the cell-targeting moiety comprises:




155. The compound of claim 135, wherein the cell-targeting moiety comprises:




156. The compound of claim 135, wherein the cell-targeting moiety comprises:




157. The compound of claim 135, wherein the cell-targeting moiety comprises:




158. The compound of claim 135, wherein the cell-targeting moiety has the following structure:



159. The compound of claim 135, wherein the cell-targeting moiety comprises:




160. The compound of claim 135, wherein the cell-targeting moiety has the following structure:



.


161. The compound of claim 135, wherein the cell-targeting moiety comprises:



;

wherein each Y is selected from O, S, a substituted or unsubstituted C_1-C_{10} alkyl, amino, substituted amino, azido, alkenyl or alkynyl.


162. The compound of claim 135, wherein the conjugate group comprises:



;

wherein each Y is selected from O, S, a substituted or unsubstituted C_1-C_{10} alkyl, amino, substituted amino, azido, alkenyl or alkynyl.


163. The compound of claim 135, wherein the cell-targeting moiety has the following structure:




;

wherein each Y is selected from O, S, a substituted or unsubstituted C_1-C_{10} alkyl, amino, substituted amino, azido, alkenyl or alkynyl.


164. The compound of any of claims 1 to 163, wherein the conjugate group comprises:




165. The compound of any of claims 1 to 164, wherein the conjugate group comprises:



166. The compound of any of claims 1 to 164, wherein the conjugate group comprises:



167. The compound of claim 166, wherein the conjugate group comprises:



168. The compound of any of claims 1 to 167, wherein the conjugate group comprises a cleavable moiety selected from among: a phosphodiester, an amide, or an ester.


169. The compound of any of claims 1 to 168, wherein the conjugate group comprises a phosphodiester cleavable moiety.

170. The compound of any of claims 1 to 169, wherein the conjugate group does not comprise a cleavable moiety, and wherein the conjugate group comprises a phosphorothioate linkage between the conjugate group and the oligonucleotide.

171. The compound of any of claims 1 to 170, wherein the conjugate group comprises an amide cleavable moiety.

172. The compound of any of claims 1 to 171, wherein the conjugate group comprises an ester cleavable moiety.

173. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein each n is, independently, from 1 to 20;

Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

174. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein each n is, independently, from 1 to 20;

Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

175. The compound of any of claims 1 to 172, wherein the compound has the following structure:



wherein each n is, independently, from 1 to 20;


Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide;

Z is H or a linked solid support; and

Bx is a heterocyclic base moiety.

176. The compound of any of claims 1 to 172, wherein the compound has the following structure:



wherein each n is, independently, from 1 to 20;


Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide;

Z is H or a linked solid support; and

Bx is a heterocyclic base moiety.

177. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide;and

Bx is a heterocyclic base moiety.

178. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide;and

Bx is a heterocyclic base moiety.

179. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

180. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

181. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

182. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

183. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

184. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

185. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

186. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

187. The compound of any of claims 1 to 172, wherein the compound has the following structure:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

188. The compound of any of claims 1 to 172, wherein the conjugate group comprises:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

189. The compound of any of claims 1 to 172, wherein the conjugate group comprises:




wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

200. The compound of any of claims 1 to 172, wherein the conjugate group comprises:



wherein Q_{13} is H or $O(CH_2)_2$-OCH_3;

A is the modified oligonucleotide; and

Bx is a heterocyclic base moiety.

201. The compound of any of claims 173 to 200, wherein B_x is selected from among from adenine, guanine, thymine, uracil, or cytosine, or 5-methyl cytosine.

202. The compound of any of claims 173 to 200, wherein B_x is adenine.

203. The compound of any of claims 173 to 200, wherein B_x is thymine.

204. The compound of any of claims 173 to 200, wherein Q_{13} is $O(CH_2)_2$-OCH_3.

205. The compound of any of claims 173 to 200, wherein Q_{13} is H.

206. A compound comprising ISIS 696844, ISIS 696845, ISIS 698969, or ISIS 698970.

207. A compound consisting of ISIS 696844, ISIS 696845, ISIS 698969, or ISIS 698970.

208. A composition comprising the compound of any of claims 1-207 or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent.

209. A prodrug comprising the compound of any of claims 1 to 208.

210. A method of treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway in a subject comprising administering to the subject the compound of any one of claims 1-207, the composition of claim 208, or the prodrug of claim 209, thereby treating, preventing, or ameliorating the disease.

211. The method of claim 210, wherein the complement alternative pathway is activated greater than normal.

212. The method of claim 210 or 211, wherein the disease is macular degeneration.

213. The method of claim 212, wherein the macular degeneration is age related macular degeneration (AMD)

214. The method of claim 213, wherein the AMD is wet AMD.

215. The method of claim 213, wherein the AMD is dry AMD.

216. The method of claim 215, wherein the dry AMD is Geographic Atrophy.

217. The method of claim 210 or 211, wherein the disease is a kidney disease.

218. The method of claim 217, wherein the kidney disease is lupus nephritis.

219. The method of claim 217, wherein the kidney disease is systemic lupus erythematosus (SLE)

220. The method of claim 217, wherein the kidney disease is dense deposit disease (DDD).

221. The method of claim 217, wherein the kidney disease is C3 glomerulonephritis (C3GN).

222. The method of claim 217, wherein the kidney disease is CFHR5 nephropathy.

223. The method of claim 217, wherein the kidney disease is atypical hemolytic uremic syndrome (aHUS).

224. The method of claim 223, wherein the aHUS is characterized by thrombotic microangiopathy.

225. The method of any one of claims 217-224, wherein the kidney disease is associated with C3 deposits.

226. The method of claim 225, wherein the kidney disease is associated with C3 deposits in the glomerulus.

227. The method of any one of claims 217-226, wherein the kidney disease is associated with lower than normal circulating C3 levels.

228. The method of claim 227, wherein the circulating C3 levels are serum or plasma C3 levels.

229. The method of any one of claims 210-216, wherein administering the compound or composition reduces or inhibits accumulation of ocular C3 levels.

230. The method of claim 229, wherein the C3 levels are C3 protein levels.

231. The method of any one of claims 210-216, wherein administering the compound or composition reduces the level of ocular C3 deposits or inhibits accumulation of ocular C3 deposits.

232. The method of any one of claims 229-231, wherein the compound or composition is administered to the subject parenterally.

233. The method of any one of claims 217-228, wherein administering the compound or composition reduces or inhibits accumulation of C3 levels in the kidney.

234. The method of claim 233, wherein the C3 levels are C3 protein levels.

235. The method of claim 233 or 234, wherein administering the compound or composition reduces the level of kidney C3 deposits or inhibits accumulation of kidney C3 deposits.

236. The method of any one of claims 233-235, wherein the C3 levels in the kidney are C3 levels in the glomerulus.

237. The method of any one of claims 233-236, wherein the compound or composition is administered to the subject parenterally.

238. The method of any one of claims 210-237, wherein the subject is identified as having or at risk of having a disease associated with dysregulation of the complement alternative pathway.

239. The method of claim 238, wherein the identification comprises detecting complement levels or membrane-attack complex levels in the subject's serum.

240. The method of claim 238, wherein the identification comprises performing a genetic test for gene mutations of complement factors associated with the disease.

241. A method of inhibiting expression of Complement Factor B (CFB) in a subject having, or at risk of having, a disease associated with dysregulation of the complement alternative pathway comprising administering the compound of any one of claims 1-207, the composition of claim 208, or the prodrug of claim 209 to the subject, thereby inhibiting expression of CFB in the subject.

242. The method of claim 241, wherein the complement alternative pathway is activated greater than normal.

243. The method of claim 241 or 242, wherein administering the compound or composition inhibits expression of CFB in the eye.

244. The method of claim 243, wherein the subject has, or is at risk of having, age related macular degeneration (AMD).

245. The method of claim 241 or 242, wherein administering the compound or composition inhibits expression of CFB in the kidney.

246. The method of claim 245, wherein administering the compound or composition inhibits expression of CFB in the glomerulus.

247. The method of claim 245 or 246, wherein the subject has, or is at risk of having, lupus nephritis, dense deposit disease (DDD), C3 glomerulonephritis (C3GN), CFHR5 nephropathy, or atypical hemolytic uremic syndrome (aHUS), or any combination thereof.

248. A method of reducing or inhibiting accumulation of C3 deposits in the eye of a subject having, or at risk of having, a disease associated with dysregulation of the complement alternative pathway comprising administering the compound of any one of claims 1-207, the composition of claim 208, or the prodrug of claim 209 to the subject, thereby reducing or inhibiting accumulation of C3 deposits in the eye of the subject.

249. The method of claim 248, wherein the complement alternative pathway is activated greater than normal.

250. The method of claim 248 or 249, wherein the subject has, or is at risk of having, age related macular degeneration (AMD).

251. A method of reducing or inhibiting accumulation of C3 deposits in the kidney of a subject having, or at risk of having, a disease associated with dysregulation of the complement alternative pathway comprising administering the compound of any one of claims 1-207, the composition of claim 208, or the prodrug of claim 209 to the subject, thereby reducing or inhibiting accumulation of C3 deposits in the kidney of the subject.

252. The method of claim 251, wherein the complement alternative pathway is activated greater than normal.

253. The method of claim 251 or 252, wherein the subject has, or is at risk of having, lupus nephritis, dense deposit disease (DDD), C3 glomerulonephritis (C3GN), CFHR5 nephropathy, or atypical hemolytic uremic syndrome (aHUS), or any combination thereof.

254. The method of any one of claims 241-253, wherein the compound or composition is administered to the subject parenterally.

255. Use of the compound of any one of claims 1-207, the composition of claim 208, or the prodrug of claim 209 for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway.

256. The use of claim 255, wherein the complement alternative pathway is activated greater than normal.

257. The use of claim 255 or 256, wherein the disease is macular degeneration.

258. The use of claim 257, wherein the macular degeneration is age related macular degeneration (AMD).

259. The use of claim 258, wherein the AMD is wet AMD.

260. The use of claim 258, wherein the AMD is dry AMD.

261. The use of claim 260, wherein the dry AMD is Geographic Atrophy.

262. The use of claim 255 or 256, wherein the disease is a kidney disease.

263. The use of claim 262, wherein the kidney disease is lupus nephritis, dense deposit disease (DDD), C3 glomerulonephritis (C3GN), CFHR5 nephropathy, or atypical hemolytic uremic syndrome (aHUS), or any combination thereof.

What is Claimed:


1. A compound comprising a single stranded modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 16 to 30 linked nucleosides and has a nucleobase sequence comprising any one of SEQ ID NOs: 455, 237, 448, 453, 444, 450, 598, 198, 549 and 228 wherein the modified oligonucleotide has:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nuclesides;

and a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar; wherein the conjugate group comprises:



and wherein the compound is capable of inhibiting Complement Factor B (CFB) expression.

2. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 455, 237, 453, 444, 448, 450, 198 or 228 wherein the modified oligonucleotide has:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides; and

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing

segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage and wherein each cytosine is a 5-methylcytosine.

3. The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 598, wherein the modified oligonucleotide has:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the 5' wing segment comprises a 2'-O-methoxyethyl sugar, 2'-O-methoxyethyl sugar and cEt sugar in the 5' to 3' direction; wherein the 3' wing segment comprises a cEt sugar, cEt sugar, and 2'-O-methoxyethyl sugar in the 5' to 3' direction; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

4. The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 549, wherein the modified oligonucleotide has:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

5. The compound of claim 1, wherein the oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to SEQ ID NO: 1 or 2.

6. The compound of claim 1 or claim 5, wherein the modified sugar is a bicyclic sugar, optionally wherein the bicyclic sugar is selected from the group consisting of: 4'-(CH2)-O-2' (LNA); 4'-(CH2) 2-O-2' (ENA); and 4'-CH(CH3)-O-2' (cEt).

7. The compound of any one of claims 1, 5 or 6, wherein the modified sugar is a 2'-O-

methoxyethyl.

8. The compound of claim 1, or any one of claims 5 – 7, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage or at least one modified nucleobase.

9. The compound of claim 8, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage or, wherein each internucleoside linkage of the modified oligonucleotide comprises a phosphorothioate internucleoside linkage.

10. The compound of claim 8 or claim 9, wherein the modified nucleobase is a 5-methylcytosine.

11. The compound of any one of claims 1 – 10, wherein the conjugate group is linked to the modified oligonucleotide:

(i) at the 5’ end of the modified oligonucleotide; or

(ii) at the 3’ end of the modified oligonucleotide.

12. A composition comprising the compound of any one of claims 1-11 or a salt thereof and at least one of a pharmaceutically acceptable carrier or diluent.

13. A compound according to any one of claims 1-11 or a composition according to claim 12 for use as a medicament.

14. Use of a compound according to any one of claims 1-11 or a composition according to claim 12 in the manufacture of a medicament for the treatment of a disease associated with dysregulation of the complement alternative pathway in a subject.

15. The use of claim 14 wherein the disease is macular degeneration, age related macular degeneration (AMD), wet AMD, dry AMD or Geographic Atrophy.

16. The use of claim 14 wherein the disease is a kidney disease.

17. The use of claim 16 wherein the kidney disease is lupus nephritis, systemic lupus erythematosus (SLE), dense deposit disease (DDD), C3 glomerulonephritis (C3GN), CFHR5 nephropathy or atypical hemolytic uremic syndrome (aHUS).